首页 > 最新文献

The Lancet Diabetes & Endocrinology最新文献

英文 中文
Continuous ketone monitoring for people with diabetes: international expert recommendations on the application of a new technology 糖尿病患者持续酮监测:国际专家关于新技术应用的建议
IF 44.5 1区 医学 Q1 ENDOCRINOLOGY & METABOLISM Pub Date : 2025-12-09 DOI: 10.1016/s2213-8587(25)00331-6
Ketan Dhatariya, Richard M Bergenstal, Mohammed Al-Sofiani, Anastasia Albanese-O’Neill, Tadej Battelino, Kelly Close, Christophe De Block, Sanjoy Dutta, Rodolfo J Galindo, Amin GhavamiNejad, Ahmad Haidar, Julie Heverly, Davida Kruger, Lori M Laffel, Julianne Lally, David M Maahs, Claudio Maffeis, Chantal Mathieu, Eden Miller, Medha Munshi, Rimei Nishimura, Kirsten Nørgaard, Tal Oron, David N O’Neal, Monica Oxenreiter, Bruce A Perkins, Moshe Phillip, Eric Renard, Jonathan Rosen, Mauro Scharf, Jennifer Sherr, Carol Wysham, Thomas Danne
The ability to reduce the risk of developing diabetic ketoacidosis (DKA) remains a major care gap for people with diabetes, particularly those on intensive insulin therapy. The anticipated availability of continuous ketone monitoring (CKM) has the potential to reduce the risk of developing DKA, one of the most life-threatening acute complications of type 1 and type 2 diabetes. International clinical guidelines have established ketone thresholds for suspected and confirmed diagnoses of DKA, based on use of point-of-care testing, as part of a triad of markers with allied thresholds for hyperglycaemia and acidosis. The increasing occurrence of euglycemic DKA, with glucose concentrations below established diagnostic thresholds, makes the availability and use of CKM technology an important addition to the diabetes management toolkit. CKM data could alert the user when the risk of acute DKA is high on sick days in addition to signalling that individuals might be predicted to be at greater overall risk of future DKA on the basis of the distribution and degree of ketone measures in daily life. If widespread use of CKM devices is to be safe and effective in reducing the occurrence of DKA, it is important to establish clear ketone thresholds which notify CKM users when action on their part is required. In defining these thresholds and actions, it was important to ensure that the CKM user is not exposed to avoidable anxiety or suffers alarm fatigue, thus adding to the burden of living with diabetes. In the absence of substantial evidence that can identify appropriate ketone thresholds for CKM use, a panel of international experts in the management of DKA was convened with the aim of developing a number of objective, practical recommendations on how this novel diabetes technology could improve outcomes for individuals at risk of DKA, the results of which we report in this Personal View. These recommendations have been endorsed by the International Society for Pediatric and Adolescent Diabetes (ISPAD).
降低糖尿病酮症酸中毒(DKA)风险的能力仍然是糖尿病患者,特别是那些接受强化胰岛素治疗的患者的主要护理差距。持续酮监测(CKM)的预期可用性有可能降低发生DKA的风险,DKA是1型和2型糖尿病最危及生命的急性并发症之一。国际临床指南基于使用即时检测,确定了疑似和确诊DKA的酮阈值,作为与高血糖和酸中毒相关阈值的三种标记物的一部分。血糖浓度低于既定诊断阈值的正血糖型DKA的发生率越来越高,这使得CKM技术的可用性和使用成为糖尿病管理工具包的重要补充。CKM数据可以提醒用户,当病假期间急性DKA的风险很高时,此外还可以根据日常生活中酮的分布和程度来预测个体未来患DKA的总体风险。如果广泛使用CKM装置安全有效地减少DKA的发生,重要的是建立明确的酮阈值,以便在需要采取行动时通知CKM使用者。在定义这些阈值和行动时,重要的是要确保CKM使用者不会暴露于可避免的焦虑或遭受警报疲劳,从而增加糖尿病患者的生活负担。由于缺乏能够确定适当的酮类阈值的实质性证据,我们召集了一个DKA管理方面的国际专家小组,目的是就这种新型糖尿病技术如何改善DKA风险个体的预后提出一些客观、实用的建议,我们在这篇个人观点中报告了结果。这些建议得到了国际儿科和青少年糖尿病学会(ISPAD)的认可。
{"title":"Continuous ketone monitoring for people with diabetes: international expert recommendations on the application of a new technology","authors":"Ketan Dhatariya, Richard M Bergenstal, Mohammed Al-Sofiani, Anastasia Albanese-O’Neill, Tadej Battelino, Kelly Close, Christophe De Block, Sanjoy Dutta, Rodolfo J Galindo, Amin GhavamiNejad, Ahmad Haidar, Julie Heverly, Davida Kruger, Lori M Laffel, Julianne Lally, David M Maahs, Claudio Maffeis, Chantal Mathieu, Eden Miller, Medha Munshi, Rimei Nishimura, Kirsten Nørgaard, Tal Oron, David N O’Neal, Monica Oxenreiter, Bruce A Perkins, Moshe Phillip, Eric Renard, Jonathan Rosen, Mauro Scharf, Jennifer Sherr, Carol Wysham, Thomas Danne","doi":"10.1016/s2213-8587(25)00331-6","DOIUrl":"https://doi.org/10.1016/s2213-8587(25)00331-6","url":null,"abstract":"The ability to reduce the risk of developing diabetic ketoacidosis (DKA) remains a major care gap for people with diabetes, particularly those on intensive insulin therapy. The anticipated availability of continuous ketone monitoring (CKM) has the potential to reduce the risk of developing DKA, one of the most life-threatening acute complications of type 1 and type 2 diabetes. International clinical guidelines have established ketone thresholds for suspected and confirmed diagnoses of DKA, based on use of point-of-care testing, as part of a triad of markers with allied thresholds for hyperglycaemia and acidosis. The increasing occurrence of euglycemic DKA, with glucose concentrations below established diagnostic thresholds, makes the availability and use of CKM technology an important addition to the diabetes management toolkit. CKM data could alert the user when the risk of acute DKA is high on sick days in addition to signalling that individuals might be predicted to be at greater overall risk of future DKA on the basis of the distribution and degree of ketone measures in daily life. If widespread use of CKM devices is to be safe and effective in reducing the occurrence of DKA, it is important to establish clear ketone thresholds which notify CKM users when action on their part is required. In defining these thresholds and actions, it was important to ensure that the CKM user is not exposed to avoidable anxiety or suffers alarm fatigue, thus adding to the burden of living with diabetes. In the absence of substantial evidence that can identify appropriate ketone thresholds for CKM use, a panel of international experts in the management of DKA was convened with the aim of developing a number of objective, practical recommendations on how this novel diabetes technology could improve outcomes for individuals at risk of DKA, the results of which we report in this Personal View. These recommendations have been endorsed by the International Society for Pediatric and Adolescent Diabetes (ISPAD).","PeriodicalId":48790,"journal":{"name":"The Lancet Diabetes & Endocrinology","volume":"15 1","pages":"82-92"},"PeriodicalIF":44.5,"publicationDate":"2025-12-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145731078","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Genetic risk-targeted islet autoantibody screening for presymptomatic type 1 diabetes in adults 成人症状前1型糖尿病的遗传风险靶向胰岛自身抗体筛查
IF 44.5 1区 医学 Q1 ENDOCRINOLOGY & METABOLISM Pub Date : 2025-12-09 DOI: 10.1016/s2213-8587(25)00318-3
N J Thomas, A Long, K Gillespie, D P Fraser, A Hill, L Ferrat, C Evans-Molina, T McDonald, R Nice, A Jones, A T Hattersley, W A Hagopian, R A Oram
{"title":"Genetic risk-targeted islet autoantibody screening for presymptomatic type 1 diabetes in adults","authors":"N J Thomas, A Long, K Gillespie, D P Fraser, A Hill, L Ferrat, C Evans-Molina, T McDonald, R Nice, A Jones, A T Hattersley, W A Hagopian, R A Oram","doi":"10.1016/s2213-8587(25)00318-3","DOIUrl":"https://doi.org/10.1016/s2213-8587(25)00318-3","url":null,"abstract":"","PeriodicalId":48790,"journal":{"name":"The Lancet Diabetes & Endocrinology","volume":"66 1","pages":"11-13"},"PeriodicalIF":44.5,"publicationDate":"2025-12-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145731074","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Social learning theories and metabolic health: the centenary of Bandura's birth 社会学习理论与代谢健康:班杜拉诞辰一百周年
IF 44.5 1区 医学 Q1 ENDOCRINOLOGY & METABOLISM Pub Date : 2025-12-03 DOI: 10.1016/s2213-8587(25)00392-4
Marta Koch, Daniel McQueen, Lorena Terclavers, Naveed Sattar
{"title":"Social learning theories and metabolic health: the centenary of Bandura's birth","authors":"Marta Koch, Daniel McQueen, Lorena Terclavers, Naveed Sattar","doi":"10.1016/s2213-8587(25)00392-4","DOIUrl":"https://doi.org/10.1016/s2213-8587(25)00392-4","url":null,"abstract":"","PeriodicalId":48790,"journal":{"name":"The Lancet Diabetes & Endocrinology","volume":"29 1","pages":""},"PeriodicalIF":44.5,"publicationDate":"2025-12-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145689536","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
The urgent need for a diabetes data rights charter. 迫切需要制定糖尿病数据权利宪章。
IF 41.8 1区 医学 Q1 ENDOCRINOLOGY & METABOLISM Pub Date : 2025-12-01 Epub Date: 2025-10-21 DOI: 10.1016/S2213-8587(25)00291-8
Laura Downey, Hanne Ballhausen, Louise Hatherall, Holly Hayes, Shane O'Donnell
{"title":"The urgent need for a diabetes data rights charter.","authors":"Laura Downey, Hanne Ballhausen, Louise Hatherall, Holly Hayes, Shane O'Donnell","doi":"10.1016/S2213-8587(25)00291-8","DOIUrl":"10.1016/S2213-8587(25)00291-8","url":null,"abstract":"","PeriodicalId":48790,"journal":{"name":"The Lancet Diabetes & Endocrinology","volume":" ","pages":"999"},"PeriodicalIF":41.8,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145369123","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Recent advances in research and care of familial hypercholesterolaemia. 家族性高胆固醇血症的研究与治疗进展。
IF 41.8 1区 医学 Q1 ENDOCRINOLOGY & METABOLISM Pub Date : 2025-12-01 Epub Date: 2025-10-22 DOI: 10.1016/S2213-8587(25)00286-4
Raul D Santos, Samuel S Gidding, Mafalda Bourbon, Iulia Iatan, Mariko Harada-Shiba, Frederick J Raal, Antonio J Vallejo-Vaz, Albert Wiegman, Gerald F Watts

Heterozygous familial hypercholesterolaemia is a common, autosomal semi-dominant condition characterised by elevation of LDL cholesterol from birth and early onset of atherosclerotic cardiovascular disease. With major advances in knowledge about the disease, familial hypercholesterolaemia has become an exemplar for the practice of precision and personalised medicine. Beyond genetics, developments in clinical risk prediction algorithms and cardiovascular imaging have enabled more accurate risk stratification of patients. Early initiation of cholesterol-lowering therapies can reduce the progression of atherosclerosis and prevent cardiovascular events. Newer treatments offer the possibility of normalising plasma LDL cholesterol concentrations even in homozygous familial hypercholesterolaemia, the most severe form of the condition. Despite these advances, familial hypercholesterolaemia is still inadequately diagnosed and undertreated, with many affected people remaining at high risk of early cardiovascular disease. The application of implementation science to expanding knowledge of familial hypercholesterolaemia has enabled the development and design of potentially more effective models of care. This Review discusses the contemporary knowledge of familial hypercholesterolaemia and its unmet clinical needs.

杂合子家族性高胆固醇血症是一种常见的常染色体半显性疾病,其特征是出生时LDL胆固醇升高和动脉粥样硬化性心血管疾病的早期发病。随着对这种疾病知识的重大进步,家族性高胆固醇血症已成为精确和个性化医疗实践的典范。除了遗传学,临床风险预测算法和心血管成像的发展使患者的风险分层更加准确。早期开始降胆固醇治疗可以减少动脉粥样硬化的进展,预防心血管事件。新的治疗方法提供了使血浆低密度脂蛋白胆固醇浓度正常化的可能性,即使是纯合子家族性高胆固醇血症,也是最严重的一种疾病。尽管取得了这些进展,家族性高胆固醇血症仍未得到充分诊断和治疗,许多受影响的人仍处于早期心血管疾病的高风险中。应用实施科学来扩大家族性高胆固醇血症的知识,使得开发和设计潜在的更有效的护理模式成为可能。本综述讨论了家族性高胆固醇血症的当代知识及其未满足的临床需求。
{"title":"Recent advances in research and care of familial hypercholesterolaemia.","authors":"Raul D Santos, Samuel S Gidding, Mafalda Bourbon, Iulia Iatan, Mariko Harada-Shiba, Frederick J Raal, Antonio J Vallejo-Vaz, Albert Wiegman, Gerald F Watts","doi":"10.1016/S2213-8587(25)00286-4","DOIUrl":"10.1016/S2213-8587(25)00286-4","url":null,"abstract":"<p><p>Heterozygous familial hypercholesterolaemia is a common, autosomal semi-dominant condition characterised by elevation of LDL cholesterol from birth and early onset of atherosclerotic cardiovascular disease. With major advances in knowledge about the disease, familial hypercholesterolaemia has become an exemplar for the practice of precision and personalised medicine. Beyond genetics, developments in clinical risk prediction algorithms and cardiovascular imaging have enabled more accurate risk stratification of patients. Early initiation of cholesterol-lowering therapies can reduce the progression of atherosclerosis and prevent cardiovascular events. Newer treatments offer the possibility of normalising plasma LDL cholesterol concentrations even in homozygous familial hypercholesterolaemia, the most severe form of the condition. Despite these advances, familial hypercholesterolaemia is still inadequately diagnosed and undertreated, with many affected people remaining at high risk of early cardiovascular disease. The application of implementation science to expanding knowledge of familial hypercholesterolaemia has enabled the development and design of potentially more effective models of care. This Review discusses the contemporary knowledge of familial hypercholesterolaemia and its unmet clinical needs.</p>","PeriodicalId":48790,"journal":{"name":"The Lancet Diabetes & Endocrinology","volume":" ","pages":"1054-1071"},"PeriodicalIF":41.8,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145370462","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Obesity legally recognised as a chronic disease in Italy. 肥胖在意大利被法律认定为一种慢性病。
IF 41.8 1区 医学 Q1 ENDOCRINOLOGY & METABOLISM Pub Date : 2025-12-01 Epub Date: 2025-10-22 DOI: 10.1016/S2213-8587(25)00326-2
Maurizio Bifulco, Cristina Pagano, Erika Di Zazzo
{"title":"Obesity legally recognised as a chronic disease in Italy.","authors":"Maurizio Bifulco, Cristina Pagano, Erika Di Zazzo","doi":"10.1016/S2213-8587(25)00326-2","DOIUrl":"10.1016/S2213-8587(25)00326-2","url":null,"abstract":"","PeriodicalId":48790,"journal":{"name":"The Lancet Diabetes & Endocrinology","volume":" ","pages":"1001-1002"},"PeriodicalIF":41.8,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145370457","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Correction to Lancet Diabetes Endocrinol 2025; 13: 909-10. 《柳叶刀糖尿病内分泌》2025修订版;13: 909 - 10。
IF 41.8 1区 医学 Q1 ENDOCRINOLOGY & METABOLISM Pub Date : 2025-12-01 Epub Date: 2025-10-21 DOI: 10.1016/S2213-8587(25)00329-8
{"title":"Correction to Lancet Diabetes Endocrinol 2025; 13: 909-10.","authors":"","doi":"10.1016/S2213-8587(25)00329-8","DOIUrl":"10.1016/S2213-8587(25)00329-8","url":null,"abstract":"","PeriodicalId":48790,"journal":{"name":"The Lancet Diabetes & Endocrinology","volume":" ","pages":"e15"},"PeriodicalIF":41.8,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145369134","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Diabetes and cancer in the age of multimorbidity 糖尿病与癌症的多病时代
IF 44.5 1区 医学 Q1 ENDOCRINOLOGY & METABOLISM Pub Date : 2025-11-26 DOI: 10.1016/s2213-8587(25)00365-1
No Abstract
没有抽象的
{"title":"Diabetes and cancer in the age of multimorbidity","authors":"","doi":"10.1016/s2213-8587(25)00365-1","DOIUrl":"https://doi.org/10.1016/s2213-8587(25)00365-1","url":null,"abstract":"No Abstract","PeriodicalId":48790,"journal":{"name":"The Lancet Diabetes & Endocrinology","volume":"4 1","pages":""},"PeriodicalIF":44.5,"publicationDate":"2025-11-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145609163","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Glycaemic control and pregnancy outcomes with real-time continuous glucose monitoring in gestational diabetes (GRACE): an open-label, multicentre, multinational, randomised controlled trial 妊娠期糖尿病实时连续血糖监测(GRACE)的血糖控制和妊娠结局:一项开放标签、多中心、多国随机对照试验
IF 44.5 1区 医学 Q1 ENDOCRINOLOGY & METABOLISM Pub Date : 2025-11-25 DOI: 10.1016/s2213-8587(25)00288-8
Tina Linder, Iris Dressler-Steinbach, Silke Wegener, Karen Schellong, Saskia Schmidt, Daniel Eppel, Cécile Monod, Florian Heinzl, Katharina Redling, Bettina Winzeler, Beatrice Mosimann, Friederike Weschenfelder, Tanja Groten, Martina Mittlböck, Johan Jendle, Wolfgang Henrich, Micaela Morettini, Latife Bozkurt, Andrea Tura, Christian Göbl, Grammata Kotzaeridi, Ingeborg Brandl, Anja Catic, Ingo Rosicky, Theresa Grill, Veronika Zehetgruber, Daniela Dittrich, Hanka Sahbegovic, Karen Weißhaupt, Luca Pfeiffer, Amelie Berg, Max Hackelöer, Vera Seidel-Eder, Petra Weid, Yvonne Heimann, Victoria Trautmann, Mirka Basten, Christina Granado, Agnese Piersanti, Michael Roden, Markus Vomhof, Gregory Greiner, Andrea Icks, Evelyn Huhn, Irene Hösli, Christian Singer
{"title":"Glycaemic control and pregnancy outcomes with real-time continuous glucose monitoring in gestational diabetes (GRACE): an open-label, multicentre, multinational, randomised controlled trial","authors":"Tina Linder, Iris Dressler-Steinbach, Silke Wegener, Karen Schellong, Saskia Schmidt, Daniel Eppel, Cécile Monod, Florian Heinzl, Katharina Redling, Bettina Winzeler, Beatrice Mosimann, Friederike Weschenfelder, Tanja Groten, Martina Mittlböck, Johan Jendle, Wolfgang Henrich, Micaela Morettini, Latife Bozkurt, Andrea Tura, Christian Göbl, Grammata Kotzaeridi, Ingeborg Brandl, Anja Catic, Ingo Rosicky, Theresa Grill, Veronika Zehetgruber, Daniela Dittrich, Hanka Sahbegovic, Karen Weißhaupt, Luca Pfeiffer, Amelie Berg, Max Hackelöer, Vera Seidel-Eder, Petra Weid, Yvonne Heimann, Victoria Trautmann, Mirka Basten, Christina Granado, Agnese Piersanti, Michael Roden, Markus Vomhof, Gregory Greiner, Andrea Icks, Evelyn Huhn, Irene Hösli, Christian Singer","doi":"10.1016/s2213-8587(25)00288-8","DOIUrl":"https://doi.org/10.1016/s2213-8587(25)00288-8","url":null,"abstract":"","PeriodicalId":48790,"journal":{"name":"The Lancet Diabetes & Endocrinology","volume":"114 1","pages":""},"PeriodicalIF":44.5,"publicationDate":"2025-11-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145592845","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Does continuous glucose monitoring deliver in gestational diabetes? 妊娠期糖尿病患者持续血糖监测是否有效?
IF 44.5 1区 医学 Q1 ENDOCRINOLOGY & METABOLISM Pub Date : 2025-11-25 DOI: 10.1016/s2213-8587(25)00297-9
Lene Ringholm
{"title":"Does continuous glucose monitoring deliver in gestational diabetes?","authors":"Lene Ringholm","doi":"10.1016/s2213-8587(25)00297-9","DOIUrl":"https://doi.org/10.1016/s2213-8587(25)00297-9","url":null,"abstract":"","PeriodicalId":48790,"journal":{"name":"The Lancet Diabetes & Endocrinology","volume":"188 1","pages":""},"PeriodicalIF":44.5,"publicationDate":"2025-11-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145592846","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
The Lancet Diabetes & Endocrinology
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1